Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBITDA: 2011-2025

Historic EBITDA for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$85.3 million.

  • Enanta Pharmaceuticals' EBITDA rose 38.41% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 29.86%. This contributed to the annual value of -$85.3 million for FY2025, which is 29.86% up from last year.
  • As of FY2025, Enanta Pharmaceuticals' EBITDA stood at -$85.3 million, which was up 29.86% from -$121.7 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' EBITDA registered a high of -$85.3 million during FY2025, and its lowest value of -$137.2 million during FY2023.
  • Its 3-year average for EBITDA is -$114.7 million, with a median of -$121.7 million in 2024.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBITDA tumbled by 163.15% in 2021 and then grew by 29.86% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' EBITDA stood at -$109.6 million in 2021, then decreased by 13.02% to -$123.8 million in 2022, then declined by 10.79% to -$137.2 million in 2023, then grew by 11.31% to -$121.7 million in 2024, then rose by 29.86% to -$85.3 million in 2025.